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Introduction {#sec001}
============

Asthma is a complex chronic inflammatory disorder of the airways with a high prevalence rate of approximately 300 million people worldwide \[[@pone.0126035.ref001]\]. Severe asthma represents approximately 5 to 10% of all subjects with asthma \[[@pone.0126035.ref002]\], but accounts for 40% of the total cost for asthma care \[[@pone.0126035.ref002]\] and 30--50% of asthma morbidity \[[@pone.0126035.ref003]\]. The National Heart, Lung, and Blood Institute's Severe Asthma Research Program (SARP) demonstrated that reduced FEV~1~ (forced expiratory volume in 1 second), history of pneumonia, and fewer positive skin tests for environmental allergens were critical independent risk factors for severe asthma \[[@pone.0126035.ref004]\]. However, the SARP study also reported that the well-established biomarkers of asthma, such as blood eosinophils, serum IgE, and exhaled nitric oxide levels, do not differentiate asthma severity or correlate with FEV~1~ or asthma severity \[[@pone.0126035.ref004]\]. The RET/ATS guidelines have been changed for defining asthma severity to controlled and uncontrolled asthma. It is important to identify specific cytokines that distinguish uncontrolled asthma from controlled asthma in the new guideline to develop novel therapeutic targets for severe asthma.

Increasing evidence suggests that inflammatory cells in the airways can distinguish severe asthma from mild asthma \[[@pone.0126035.ref005]--[@pone.0126035.ref012]\]. Because sputum samples are collected non-invasively, several studies have evaluated sputum samples, and reported higher percentages of neutrophils in the sputum in severe compared to mild asthma \[[@pone.0126035.ref007], [@pone.0126035.ref008]\]. However, because sputum neutrophil numbers do not correlate with the cell numbers in bronchoalveolar lavage (BAL) fluids from the same subjects \[[@pone.0126035.ref013]\], it is important to validate the observations of neutrophilia in the sputum by sampling other compartments of the airways. A study of tracheal aspirates from patients intubated for acute severe asthma reported a higher percentage of neutrophils compared to a control group of patients undergoing nonpulmonary surgical procedures \[[@pone.0126035.ref009]\]. In another study, patients intubated for status asthmaticus exhibited a higher mean percentage of neutrophils in their BAL fluid compared to that from patients with stable mild asthma \[[@pone.0126035.ref010]\]. We have reported that unlike classic slow-onset progressive fatal asthma, peribronchial lung tissues in sudden-onset fatal asthma had considerably more neutrophils than eosinophils \[[@pone.0126035.ref006]\]. Thus an increasing body of literature supports the idea that there is an abundance of neutrophils in severe asthma.

Many cytokines and chemokines could theoretically be associated with \"neutrophil- rich\" and "eosinophil-rich" endotypes of asthma \[[@pone.0126035.ref014]\]. However, most studies have utilized a candidate cytokine approach to quantify specific cytokines in asthma \[[@pone.0126035.ref009]--[@pone.0126035.ref012]\]. One such candidate-cytokine study evaluated sputum concentrations of IL-8, and reported higher levels in severe vs. mild asthma \[[@pone.0126035.ref007]\]. Another study evaluated IL-8 in tracheal aspirates, and reported higher levels in patients intubated for acute severe asthma compared to a control group of patients undergoing surgical procedures unrelated to the lung \[[@pone.0126035.ref009]\]. Likewise, the concentration of IL-8 in BAL fluid from patients intubated for status asthmaticus was elevated compared to mild asthma \[[@pone.0126035.ref010]\]. To our knowledge, only two study evaluated an array of over 20 cytokines and chemokines in BAL fluid to identify cytokines that distinguish severe asthma from mild or moderate asthma \[[@pone.0126035.ref015], [@pone.0126035.ref016]\]. One of these studies reported identically level of IL-8 in moderate and severe asthma in children compared to adult controls \[[@pone.0126035.ref015]\], whereas the other reported no difference in BAL fluid levels of IL-8 between mild asthma and severe asthma \[[@pone.0126035.ref016]\]. To address this difference in the observations reported in candidate-cytokine studies \[[@pone.0126035.ref009]--[@pone.0126035.ref012]\] vs. panel-cytokine study \[[@pone.0126035.ref016]\], we examined a panel of 48 cytokines and chemokines in BAL fluids from healthy control subjects and subjects with controlled and uncontrolled asthma.

Materials and Methods {#sec002}
=====================

Subjects {#sec003}
--------

Subjects were recruited in the Department of Asthma, Allergy and Lung Biology, King's College London School of Medicine, U.K. The study was approved by the Ethics Committee of King's College Hospital, and each participant provided written informed consent. Subjects with asthma were included on the basis of history and a demonstrated reversible airflow limitation (20% variability in forced expiratory volume in one second \[FEV~1~\] or peak expiratory flow rate), increased airway responsiveness to methacholine (concentration producing a decrease of 20% from base line in FEV~1~ \[PC~20~\], \< 8 mg per millilitre), or both. None had ever smoked, and there was no history of other respiratory disease. Atopy was defined as the presence of one or more positive skin prick tests to a range of common aeroallergens. The normal controls had no history of allergic disease, had normal FEV~1~, and a PC~20~ of more than 32 mg per millilitre. Of the controls, 5 of 11 were atopic. The subjects' characteristics are shown in [Table 1](#pone.0126035.t001){ref-type="table"}. These included 11 healthy control subjects (FEV~1~ = 102%, 89--110), 15 subjects with controlled asthma (Mean FEV~1~ 98%, 81--113) and 10 with uncontrolled asthma (Mean FEV~1~ 64%, 48--74, \< 80%). For the purpose of this study, we defined asthma severity based on FEV~1~ while on treatment, according to international ERS/ATS guidelines \[[@pone.0126035.ref017]\].

10.1371/journal.pone.0126035.t001

###### Patient characteristics.

![](pone.0126035.t001){#pone.0126035.t001g}

  Characteristic                    Healthy           Controlled Asthma                                      Uncontrolled Asthma
  --------------------------------- ----------------- ------------------------------------------------------ --------------------------------------------------------------------------------------------
  n                                 11                15                                                     10
  Age (yr)                          24.0 (19--38)     27.1 (19--41)                                          45.8 (29--63)[\*](#t001fn002){ref-type="table-fn"} [^+^](#t001fn003){ref-type="table-fn"}
  Sex (% male)                      45.5              40                                                     60
  Use of ICS (%)                    none              11.7                                                   100
  Mean dose of ICS                  none              27                                                     710
  Use of LABA (%)                   none              none                                                   90
  Duration of asthma, (yr)          NA                4.7 (3--13)                                            10.0 (6--20)
  Atopy, %                          54.5              66.7                                                   70
  FEV1, % predicted                 102.0 (89--118)   98.1 (83--113)                                         64.1 (48--74) [\*](#t001fn002){ref-type="table-fn"} [^+^](#t001fn003){ref-type="table-fn"}
  Total IgE (IU/ml)                 49.6 (17--232)    86.7 (19--623) [\*](#t001fn002){ref-type="table-fn"}   123.2 (18--721) [\*](#t001fn002){ref-type="table-fn"}
  Blood eosinophils (%leukocytes)   0.6 (0.2--2.6)    2.1 (0.6--3.2) [\*](#t001fn002){ref-type="table-fn"}   2.9 (0.4--4.1) [\*](#t001fn002){ref-type="table-fn"}

Results expressed in means and range.

\*Statistical significant compared to healthy group

^+^Statistical significant compared to controlled asthma

Fiberoptic bronchoscopy and collection of BAL fluid {#sec004}
---------------------------------------------------

Fiberoptic bronchoscopy was performed, and BAL fluid obtained and processed as previously described \[[@pone.0126035.ref018]\]. Briefly, bronchoscopy was performed by the same operator in both the asthmatics and the controls after they had received 2.5 mg of albuterol by nebulizer, 0.6 mg of atropine, midazolam for sedation, and 2% or 4% of lidocaine for local anaesthesia. BAL was performed by instilling four 60-ml aliquots of warmed, pH-adjusted, normal saline into either the right middle lobe or the lingula. After collection, BAL cells were centrifuged at 300 x g for 7 min, washed once, and resuspended in 1.5 mL of PBS; BAL fluid supernatants were distributed into 10 ml each tube and stored at -80°C for further analysis (up to 3 years). The mean total amount of BAL fluid was 92ml.

Cell counts in BAL fluid {#sec005}
------------------------

Cytospin slides of BAL cells were made with a Shandon 2 cytospin device (Shandon Southern Instruments, Runcorn, UK). For cell differentiation, slides were stained with May-Grunwald Giemsa. Cell counts were performed and the absolute numbers and percentages of eosinophils, neutrophils, lymphocytes and monocytes/macrophages were quantified.

Cytokines and chemokines in BAL fluid {#sec006}
-------------------------------------

Cytokines in BAL fluid were quantified using a Bio-Plex array for 48 cytokines (Bio-Rad, Hercules, CA) according to the manufacturer's instructions: Interleukin (IL)-1α, IL-1β, IL-1 receptor antagonist (IL-1RA), IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-16, IL-17, IL-18, fibroblast growth factor (FGF), eotaxin (CCL11), granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN)-γ, interferon gamma-induced protein (IP)-10/CXCL10, monocyte chemotactic protein (MCP)-1/CCL2, macrophage inflammatory protein (MIP)-1α/CCL3, MIP-1β/CCL4, platelet-derived growth factor (PDGF), regulated-on-activation normal T-cell expressed and secreted (RANTES)/CCL5, tumor necrosis factor (TNF)-α, vascular endothelial growth factor (VEGF), cutaneous T cell attracting chemokine (CTACK)/ CCL27, growth regulated oncogene α (GROα)/ CXCL1, hepatocyte growth factor (HGF), IFN-α2, leukemia inhibitory factor (LIF), MCP-3/CCL7, macrophage colony-stimulating factor (M-CSF), macrophage migration inhibitory factor (MIF), monokine induced by interferon-gamma (MIG)/CXCL9, nerve growth factor-β (NGF-β), stem cell factor (SCF), stem cell growth factor-β (SCGF-β), stromal cell-derived factor-1α (SDF-1α), TNF-β, and TNF-related-apoptosis-induced- ligand (TRAIL). The lower limits of detection of cytokines that were not detected (ND) or were at borderline limits of detection were: IL-2 (3 pg/ml), IL-4 (6 pg/ml), IL-13 (4 pg/ml), IL-17 (48 pg/ml), FGF (172.4pg/ml), CCL3 (178 pg/ml), CCL11 (325 pg/ml), GM-CSF (22 pg/ml), and TNF-α (543 pg/ml).

Statistical Analysis {#sec007}
--------------------

The results of the study are presented as means ± SEM. Group comparisons were analyzed by an unpaired Student's *t*-test or one-way ANOVA with Tukey\'s multiple comparisons test. The Holm procedure was used for multiple comparison adjustment. Linear regression analysis was performed to assess the relationship among parameters. For the logistic regression comparing asthmatic and healthy subjects, an elastic net regression was used with leave-half-out validation for model selection and error estimation. For the logistic regression comparing controlled to uncontrolled asthma, a least squares regression predicting FEV~1~%, stepwise selection was used with the Bayesian Information Criterion as the model selection criterion. All calculations were performed in R (version 3.0.2). The software package GraphPad Prism 6 (GraphPad Software, San Diego, CA) was used for the preparation of graphs. Statistical significance was set at p\<0.05.

Results {#sec008}
=======

Differences in BAL fluid cellular and cytokine profiles of subjects with asthma vs. healthy controls {#sec009}
----------------------------------------------------------------------------------------------------

Compared to healthy control subjects (n = 11), subjects with asthma (n = 25) had higher % eosinophils (p\<0.001) and %neutrophils (p\<0.05) in their BAL fluids ([Fig 1A](#pone.0126035.g001){ref-type="fig"}). Furthermore, subjects with asthma had 2.3-fold higher IL-1RA (p\<0.001), 2.0-fold higher IL-1α (p\<0.05), 2.5-fold higher IL-1β (p\<0.01), 1.3-fold higher IL-2Rα (p\<0.05), 1.7-fold higher IL-5 (p\<0.05), 3.2-fold higher IL-6 (p\<0.001), 1.4-fold higher IL-7 (p\<0.05), 1.7-fold higher IL-8 (p\<0.001), 2.2-fold higher G-CSF (p\<0.05), 1.7-fold higher CXCL1 (p\<0.05), 1.4-fold higher CCL4 (p\<0.05), 1.7-fold higher CXCL9 (p\<0.01), 2.0-fold higher CCL5 (p\<0.01) and 1.9-fold higher TRAIL (p\<0.05) concentrations in their BAL fluids ([Fig 1B](#pone.0126035.g001){ref-type="fig"}). By contrast, subjects with asthma and healthy controls had similar mean concentrations of such other cytokines as IL-3, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-16, IL-18, IFN-γ, IFN-α2, CXCL10, CCL2, CCL3, PDGF-bb, VEGF, CCL27, HGF, LIF, CCL7, M-CSF, MIF, NGF-β, SCF, SCGF-β, SDF-1α and TNF-β ([Table 2](#pone.0126035.t002){ref-type="table"}). IL-2, IL-4, IL-17, CCL11, FGF, GM-CSF, and TNF-α were not detected in either group. Thus, 14 out of 48 cytokines were higher in subjects with asthma, compared to healthy control subjects.

![Differences in cell and cytokine levels in BAL fluids in healthy controls vs. asthma.\
(A) Percentages of eosinophils and neutrophils in the BAL fluids. (B) Concentrations of IL-1RA, IL-1α, IL-1β, IL-2Rα, IL-5, IL-6, IL-7, IL-8, G-CSF, CXCL1, CCL4, CXCL9, CCL5, and TRAIL in the BAL fluids. Data are expressed as means ± SEM. \* = *P* \< .05, \*\* = *P* \< .01, \*\*\* = *P* \< .001, \*\*\*\* = *P* \< .0001.](pone.0126035.g001){#pone.0126035.g001}

10.1371/journal.pone.0126035.t002

###### Cellular and cytokine profile in BAL fluid without statistical difference between subjects with asthma and healthy controls.

![](pone.0126035.t002){#pone.0126035.t002g}

  Cellular component and cytokines   Healthy           Asthmatic
  ---------------------------------- ----------------- -----------------
  IL-2 (pg/ml)                       ND                ND
  IL-3 (pg/ml)                       90.4±103.9        138.2±110.2
  IL-4 (pg/ml)                       ND                ND
  IL-9 (pg/ml)                       25.0±9.8          31.5±10.9
  IL-10 (pg/ml)                      12.8±12.5         14.3±11.9
  IL-12 (p40) (pg/ml)                693.5±231.0       811.8±240.4
  IL-12 (p70) (pg/ml)                237.1±82.0        233.1±94.4
  IL-13 (pg/ml)                      12.0±5.2          14.3±6.3
  IL-15 (pg/ml)                      6.1±4.5           5.8±3.8
  IL-16 (pg/ml)                      1034.1±935.3      1317.6±749.7
  IL-17 (pg/ml)                      ND                ND
  IL-18 (pg/ml)                      282.0±102.9       408.4±262.2
  FGF (pg/ml)                        ND                ND
  CCL11 (pg/ml)                      ND                ND
  GM-CSF (pg/ml)                     ND                ND
  IFN-α2 (pg/ml)                     105.3±57.1        126.0±47.0
  IFN-γ (pg/ml)                      73.6±70.2         88.5±89.8
  CXCL10 (pg/ml)                     13362.5±19043.1   14797.3±10298.6
  CCL2 (pg/ml)                       349.5±122.5       403.9±132.9
  CCL3 (pg/ml)                       ND                ND
  PDGF-bb (pg/ml)                    95.1±94.2         192.5±147.9
  TNF-α (pg/ml)                      ND                ND
  VEGF (pg/ml)                       3304.9±1427.3     3358.5±1534.4
  CCL27 (pg/ml)                      365.0±144.6       416.0±134.5
  HGF (pg/ml)                        554.5±286.6       748.4±324.3
  LIF (pg/ml)                        150.3±82.9        168.3±88.0
  CCL7 (pg/ml)                       522.9±301.4       588.2±243.5
  M-CSF (pg/ml)                      274.7±103.7       369.1±157.2
  MIF (pg/ml)                        9627.4±8797.7     14690.1±8929.0
  NGF-β (pg/ml)                      340.8±87.5        383.7±89.5
  SCF (pg/ml)                        413.5±222.8       450.1±203.1
  SCGF-β (pg/ml)                     775.1±546.1       647.5±498.0
  SDF-1α (pg/ml)                     1118.5±477.5      1427.2±478.7
  TNF-β (pg/ml)                      582.6±187.4       630.5±208.7

Results expressed in means and range.

ND; Not detected.

BAL cytokine profile analysis identify only IL-8 levels and % neutrophils as biomarker that distinguish controlled asthma from uncontrolled asthma, and both correlate inversely with FEV~1~ {#sec010}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Next, we determined which of these cells and 14 cytokines ([Fig 1](#pone.0126035.g001){ref-type="fig"}) elevated in asthma distinguished controlled from uncontrolled asthma. Unexpectedly, there were only two differences between these two groups. Subjects with uncontrolled asthma had a mean 1.7-fold higher percentage of neutrophils in the BAL fluid compared to those with controlled asthma (controlled asthma = 1.6±1.1%, uncontrolled asthma = 2.9±0.8%, p\<0.01, [Fig 2A](#pone.0126035.g002){ref-type="fig"}). The mean concentration of IL-8 in the BAL fluid from subjects with uncontrolled asthma was 1.5-fold higher than that in subjects with controlled asthma (controlled asthma = 1128±386 pg/ml, uncontrolled asthma = 1716±551 pg/ml, p\<0.01, [Fig 2A](#pone.0126035.g002){ref-type="fig"}). Furthermore, only IL-8 concentrations in all subjects with asthma (controlled and uncontrolled) significantly correlated with the percentages of neutrophils in the BAL fluid (R = 0.61, p\<0.01, [Fig 2B](#pone.0126035.g002){ref-type="fig"}). In addition, the percentages of neutrophils and the concentrations of IL-8 in the BAL fluid were both inversely correlated with the % predicted FEV~1~ (R = -0.46, p\<0.05 for both neutrophil% and IL-8 levels, [Fig 2B](#pone.0126035.g002){ref-type="fig"}). Even though BAL eosinophil % in all subjects with asthma correlated with BAL fluid IL-5 levels ([Fig 2C](#pone.0126035.g002){ref-type="fig"}), neither eosinophil % nor IL-5 levels correlated with % predicted FEV~1~ ([Fig 2C](#pone.0126035.g002){ref-type="fig"}). Some cytokines elevated in subjects with asthma significantly correlated with the level of IL-8 in BAL fluids: IL1-RA (R = 0.59, p\<0.01), IL-1α (R = 0.40, p\<0.05), IL-6 (R = 0.68, p\<0.001), IL-7 (R = 0.47, p\<0.05), G-CSF (R = 0.74, p\<0.0001), CCL4 (R = 0.45, p\<0.05), CXCL1 (R = 0.64, p\<0.01), and CXCL9 (R = 0.48, p\<0.05). However, these cytokines did not correlate with the % neutrophils or % predicted FEV~1~ in BAL fluids.

![Correlation of FEV1 to eosinophil, neutrophil, IL-5 and IL-8 levels in asthma.\
(A) Percentages of neutrophils and concentrations of IL-8 in BAL fluids of subjects with controlled asthma and uncontrolled asthma. (B) Correlations of concentrations of IL-8 with the percentages of neutrophils in the BAL fluid from all subjects with asthma (left panel). Correlation of percentages of neutrophils and concentrations of IL-8 in BAL fluid with percent predicted FEV~1~ (middle and right panels, respectively). (C) Correlation of concentrations of IL-5 with the percentages of eosinophil in the BAL fluid from all subjects with asthma (left panel). Correlation of percentages of eosinophils and concentrations of IL-5 in BAL fluid with percent predicted FEV~1~ (middle and right panels, respectively). Data are expressed as means ± SEM. \* = *P* \< .05, \*\* = *P* \< .01, \*\*\* = *P* \< .001, \*\*\**\* = P* \< .0001.](pone.0126035.g002){#pone.0126035.g002}

Next we statistically examined whether inhaled corticosteroid (ICS) could have contributed to some of the observations in the present study by separating all subjects with asthma into those that received ICS vs. those that did not. Subjects with asthma that were being treated with ICS had higher % neutrophils (p\<0.05), higher IL-8 levels (p\<0.05) and lower % predicted FEV~1~ (p\<0.0001). However, the dose of ICS did not correlate the level of % neutrophils and IL-8 levels in BAL fluids (data not shown).

Eosinophil-high and neutrophil-high asthma have different cytokine profiles and FEV~1~ {#sec011}
--------------------------------------------------------------------------------------

Building on the unexpected observation that % neutrophil but not % eosinophils correlated inversely with % predicted FEV~1~ in asthma, we examined whether grouping asthma subjects on the basis of BAL eosinophil % or neutrophil % could identify specific cytokine profiles. In our study, the upper limit of percent of eosinophils and neutrophils in the BAL fluid of healthy subjects was 0.3% and 2.4%, respectively (Figs [3](#pone.0126035.g003){ref-type="fig"} and [4](#pone.0126035.g004){ref-type="fig"}). For the purpose of this study, we separated all subjects with asthma into either eosinophil-high (eosinophils \> 0.3%, Eos-High) and eosinophil-normal (eosinophils≤0.3%, Eos-Normal) groups ([Fig 3](#pone.0126035.g003){ref-type="fig"}), or neutrophil-high (neutrophils% \> 2.4%, Neu-High), and neutrophil-normal (neutrophil≤2.4%, Neu-Normal) groups ([Fig 4](#pone.0126035.g004){ref-type="fig"}). Compared to Eos-Normal asthma, Eos-High asthma had higher levels of IL-5 (p\<0.05), IL-13 (p\<0.05), IL-16 (p\<0.05), and PDGF-bb (p\<0.05), but same % neutrophils, IL-8, other cytokines (data not shown), and FEV~1~ ([Fig 3](#pone.0126035.g003){ref-type="fig"}). By contrast, compared to Neu-Normal asthma, Neu-High asthma had higher IL-8 levels (p\<0.01) and lower % predicted FEV~1~ (p\<0.01), but similar levels of eosinophil %, IL-5, IL-13, IL-16, and PDGF-bb ([Fig 4](#pone.0126035.g004){ref-type="fig"}) and other cytokines and chemokines (data not shown). These results also indicate an association of Neu-High asthma with IL-8 and % FEV~1~.

![Cell and cytokine profile of eosinophil-high (Eos-High) asthma and eosinophil-normal (Eos-Normal) asthma.\
The upper limit of percent of eosinophils in the BAL fluid of healthy subjects was 0.3%. We separated all subjects with asthma into either eosinophil-high (eosinophils \> 0.3%) and eosinophil-normal (eosinophils≤0.3%) groups. Compared to Eos-Normal asthma, Eos-High asthma had higher levels of IL-5 (p\<0.05), IL-13 (p\<0.05), IL-16 (p\<0.05), and PDGF-bb (p\<0.05), but same % neutrophils, IL-8, and FEV~1~. Data are expressed as means ± SEM. \**P* \< .05, \*\**P* \< .01.](pone.0126035.g003){#pone.0126035.g003}

![Cell and cytokine profile of neutrophil-high (Neu-High) asthma and neutrophil-normal (Neu-Normal) asthma.\
The upper limit of percent of neutrophils in the BAL fluid of healthy subjects was 2.4%. We separated all subjects with asthma into neutrophil-high (neutrophils% \> 2.4%), and neutrophil-normal (neutrophil≤2.4%) groups. Compared to Neu-Normal asthma, Neu-High asthma had higher IL-8 levels (p\<0.01) and lower % predicted FEV~1~ (p\<0.01), but similar levels of eosinophil %, IL-5, IL-13, IL-16, and PDGF-bb. Data are expressed as means ± SEM. \**P* \< .05, \*\**P* \< .01.](pone.0126035.g004){#pone.0126035.g004}

Multiple regression analysis models {#sec012}
-----------------------------------

The estimated predictive equation for the presence of asthma using logistic regression was: Logit (Present (asthma)) = -3.85 + 0.0033 (IL-8) + 2.77 (% eosinophils) (p = 0.05 and 0.09, respectively). The accuracy of this model was 84%, with 89% sensitivity and 75% specificity. The predictive equation for FEV~1~% predicted in asthma was 103--0.023 (IL-8) + 0.040 (IL-1α). The R^2^ for this model was 0.34 (p = 0.0037 and 0.06, respectively). Atopy had no significant effect.

Discussion {#sec013}
==========

Prior studies have mostly measured candidate cytokines, and reported increased levels of IL-8 and neutrophils in the sputum in severe asthma \[[@pone.0126035.ref007]\]. Our study of the BAL fluid provides this specific information by demonstrating that IL-8 is the only cytokine among 48 measured that is significantly elevated in uncontrolled asthma. The higher BAL fluid IL-8 levels in uncontrolled asthma seen in our study could reflect persistent stimulation of IL-8 secretion by chronic stimulation of the nuclear factor-κB signaling pathway following exposure to environemantal factor \[[@pone.0126035.ref019]\], or intrinsic differences in the ability of uncontrolled asthma patients' airway epithelium to produce high amounts of IL-8 \[[@pone.0126035.ref020]\]. In addition to its ability to stimulate neutrophil recruitment, IL-8 may contribute to the pathogenesis of severe asthma by directly facilitating airway remodeling by increasing bronchial smooth muscle cell migration and proliferation \[[@pone.0126035.ref021]\], inducing airway hyperresponsiveness (AHR) \[[@pone.0126035.ref022]\], and stimulating epithelial-mesenchymal transition (EMT) \[[@pone.0126035.ref023]\] in the airways.

In our study, neutrophil-high asthma had lower FEV~1~, and the neutrophil percentage in asthma was inversely correlated with FEV~1~ and directly correlated with IL-8 levels. The mechanistic contribution of neutrophils to asthma severity is not well understood, and our study was not designed to address this issue. A variety of factors produced by neutrophils could theoretically contribute to the pathogenesis of severe asthma. Depletion of neutrophils in a mouse model of allergic asthma has been reported to reduce AHR and airway remodeling \[[@pone.0126035.ref024]\]. Matrix metalloproteinase 9 (MMP-9) from neutrophils has been shown to be associated with asthma severity \[[@pone.0126035.ref024]\]. Neutrophil elastase can induce AHR \[[@pone.0126035.ref025]\], and promote the EMT \[[@pone.0126035.ref026]\]. After interacting with allergens, neutrophils release α-defensins \[[@pone.0126035.ref027]\], which can stimulate IL-8 secretion from human bronchial epithelial cells \[[@pone.0126035.ref028]\]. Neutrophils from subjects with asthma produce higher TGF-β1 \[[@pone.0126035.ref029]\], a strong inducer of the EMT. Neutrophils are a major source of reactive oxygen species (ROS) generated by gp91phox NADPH oxidase \[[@pone.0126035.ref030]\], and promote allergic airway inflammation \[[@pone.0126035.ref031]\].

In our study, 12% of the subjects with controlled asthma and all subjects with uncontrolled asthma used ICS. Because steroids can inhibit apoptosis of neutrophils \[[@pone.0126035.ref032]\] and suppress eosinophil survival \[[@pone.0126035.ref033]\], use of ICS could have impacted the results of our study by skewing cell counts to higher neutrophilia in uncontrolled asthma. However, in our study the dose of ICS did not correlated the level of neutrophils in BAL fluids, suggesting that this is most likely not the explanation for higher %neutrophil. As in our study, others have also reported elevated neutrophils in severe asthma, independent of steroids. For example, the European Network for Understanding Mechanisms of Severe Asthma study also reported more neutrophils in the sputum from subjects with severe asthma, independent of corticosteroid use \[[@pone.0126035.ref034]\]. Likewise, use of inhaled corticosteroids did not impact BAL fluid IL-8 levels in a study of the molecular phenotyping of severe asthma \[[@pone.0126035.ref016]\]. Further studies are needed to clarify the effect of ICS on neutrophils and eosinophils in the airways \[[@pone.0126035.ref035]\].

Consistent with prior studies \[[@pone.0126035.ref011], [@pone.0126035.ref012], [@pone.0126035.ref036]--[@pone.0126035.ref043]\], our results also demonstrate that subjects with asthma have higher concentrations of IL-5 and the numbers of eosinophils in BAL fluid compared to control subjects. This is not surprising because eosinophilic inflammation is a significant feature of the pathology of asthma \[[@pone.0126035.ref009]--[@pone.0126035.ref012], [@pone.0126035.ref036], [@pone.0126035.ref037], [@pone.0126035.ref044]\]. In our study, eosinophils and IL-5 did not correlate with percent predicted FEV~1~. The lack of association between eosinophils and FEV~1~ in asthma is surprising because eosinophils have been shown to contribute to AHR in murine, guinea pig and mammal studies \[[@pone.0126035.ref045]--[@pone.0126035.ref048]\]. However, several human studies have shown that eosinophils do not correlate with AHR or airflow obstruction \[[@pone.0126035.ref049]--[@pone.0126035.ref051]\].

It is somewhat surprising some Th2 cytokines and chemokines, especially IL-4, IL-13, and CCL11 were not elevated in the present study, even though prior reports indicated the increase of these cytokines and chemokines \[[@pone.0126035.ref038]--[@pone.0126035.ref043], [@pone.0126035.ref052]--[@pone.0126035.ref058]\]. Two studies performed in the 1990s reported elevated IL-4 levels in concentrated BAL fluids in asthma \[[@pone.0126035.ref040], [@pone.0126035.ref041]\]. Since concentrating BAL fluid may induce a processing artifact, more recent studies have been performed on unconcentrated BAL fluids \[[@pone.0126035.ref015], [@pone.0126035.ref059]\]. Like our study that was also performed on unconcentrated BAL fluids using multiplex beads, these studies reported that IL-4 and IL-13 were undetectable in unconcentrated BAL fluids in asthma \[[@pone.0126035.ref015], [@pone.0126035.ref059]\]. Like our study, a previous study reported that there is no elevation of TNFα or GM-CSF in BAL fluids from the subjects of asthma \[[@pone.0126035.ref015]\]. Prior studies have reported an increase in CCL11 levels in BAL fluids in subjects with asthma after allergen challenge \[[@pone.0126035.ref056]\], and CCL11positive cells or CCL11 mRNA expression in bronchial biopsy specimens in asthma \[[@pone.0126035.ref057], [@pone.0126035.ref058]\]. However, other studies that were similar to ours, and sampled the BAL compartment in asthma without allergen challenge, also failed to detect CCL11 \[[@pone.0126035.ref060]\], or detected CCL11 at a level that would be too low (7--41 pg/ml) to be detectable by our kit (lower limit of detection 325 pg/ml) \[[@pone.0126035.ref015], [@pone.0126035.ref059]\].

We unexpectedly did not detect IL-17in our study. A recent study reported that IL-17 is present in BAL fluids from the subjects with asthma at mean levels of about 60 pg/ml (25--150 pg/ml) \[[@pone.0126035.ref061]\]. Since the lower limit of detection level of IL-17 in our study 48 pg/ml, this could account for failure to detect IL-17 in our study.

Recent studies have suggested that asthma is a heterogeneous disease complex that should be classified into distinct endotypes based on their cytokine profiles \[[@pone.0126035.ref015], [@pone.0126035.ref016], [@pone.0126035.ref062]--[@pone.0126035.ref065]\]. In the present study we also show there are quantitative differences in cytokine pattern between neutrophil-high asthma and eosinophil-high asthma. However, our data suggest that uncontrolled and controlled asthma have a fairly uniform cytokine profile and may have a common pathogenesis instead of being a collection of fundamentally distinct diseases. Our observations question the importance cytokine-based endotypes classification of asthma in predicting asthma severity.

The specific association of only IL-8 in 48 cytokines quantified in BAL fluids with neutrophil-high and uncontrolled asthma in the present study provides specificity to earlier candidate-cytokine studies reporting elevated IL-8 and neutrophils in severe asthma \[[@pone.0126035.ref007]--[@pone.0126035.ref010]\]. Together, these studies indicate that the mechanistic role of IL-8 and recruited neutrophils should be carefully evaluated in uncontrolled asthma. CXCR2 is one of the receptors for IL-8 \[[@pone.0126035.ref066]\]. A recent study demonstrated that CXCR2 inhibitor reduced sputum neutrophilia and asthma exacerbations, and improved Asthma Control Questionnaire (ACQ) score in patients with severe asthma \[[@pone.0126035.ref067]\]. If the results of our study are confirmed in mechanistic and large-scale BAL fluid studies, inhibition of neutrophil recruitment by CXCR2 inhibitors and others agents should be explored as alternate therapeutic strategies in uncontrolled asthma with elevated neutrophils.
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